Welcome - Home - Register - Login - Help/FAQ - 0 items

Search Enter keywords, a title or a report id number below. In All Categories --------------------- Telecom & Computing Business & Finance Mfg & Construction Pharma & Healthcare Consumer & Retail Gov & Public Sector Energy & Transport Country Reports Company Reports --------------------- Transcripts Advanced      Select a currency for use throughout the site Australia Dollars Canada Dollars Euro Japan Yen Sweden Kroner Switzerland Francs UK Pounds US Dollars Viewing report Order by Fax Printer Friendly PDF Brochure Send to Friend Enquire before Buying Electronic Pipeline Insight: Nociceptive Pain - Safety Profile Uppermost in Crowded Market Datamonitor, Oct 2004, Pages: 264   Description     Table of Contents        Enquire before Buying    Send to a Friend   Introduction The nociceptive pain pipeline contains few novel drugs, instead being filled with reformulations and drug combinations. To make a drug stand out in this replete market, particularly at a time when there is great public concern about drug withdrawals, it must have an unquestionable safety profile, proven over long-term trials. Scope Epidemiology of nociceptive pain across the seven major markets, as well as analysis of the main unmet needs in the current treatment of the disease Overview of drugs in Phase III, II, I and preclinical development, plus analysis of key companies involved in the R&D pipeline: GSK, Merck and Endo Comprehensive analysis of key late-stage products including DepoDur, Ionsys, Prexige, Prialt & THC monotherapy, with drug revenues forecast to 2014 Insight into innovative early stage products, including vanilloid and Bradykinin receptors, plus analysis of key research into gene therapy for pain Highlights Although pain is not a new phenomenon, better education for patients, physicians, nurses and pharmacists is still an unmet need. The current range of therapies should be sufficient for pain relief if used knowledgably. New COX-2 inhibiting drugs will have to provide impeccable safety data from long-term trials before gaining approval in the current climate where the whole class of drugs is suspect. If safety can be proved, the market is relatively small, and new entrants may do well. While experts believe morphine is still the most effective painkiller available, it can be improved upon in terms of convenience and side effects. Many opioids in development are reformulations of old drugssustained release, or patch deliveryor receptor-specific drugs aiming to reduce side effects. Reasons to Purchase Enhance your sales forecasting ability and future product positioning through identification of market drivers and key competitors Optimize your knowledge of company strategies in the nociceptive pain market Identify areas of the market that are not being targeted by competitors Customers who bought this item also bought Pipeline Insight: Rheumatoid Arthritis and Osteoarthritis - Striving for innovation among me-toos Pipeline Insight: Neuropathic Pain - Pipeline Drugs Fail To Nail Neuropathic Pain Competitive Strategies in Pain Management, 2001 Edition Pain Therapeutics - Drugs, Markets and Companies Pipeline Insight: HIV - Enter the New Generation Inhibitors Pipeline Insight: Depression - Novel therapies key to market penetration Pipeline Insight: Osteoporosis - Intermittent Dosing and Multiple Indications Drive Market Growth Pipeline Insight: Asthma, COPD and Allergic Rhinitis - Weak Late Stage Pipeline Leaves Innovation to Phase I/II Candidates

		Top of page

All rights reserved. Copyright 2008 Research and Markets    Terms and conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster